-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On Tuesday, Eli Lilly announced a head-to-head study to compare the effectiveness of Emgality® (galcanezumab-gnlm) and Nurtec® ODT (rimegepant) in the prevention of migraine with monthly injections
.
Emgality is a monoclonal antibody that can selectively bind to calcitonin gene-related peptide (CGRP).
The FDA approved the preventive treatment of migraine in 2018
.
At a virtual meeting organized by the American Headache Society (AHS) in 2021, according to real data in reality, the compliance and durability of migraine patients using the drug is higher than that of oral standard treatment
.
Nurtec is an orally disintegrating tablet that patients take every other day
.
Unlike Emgality, Nurtec works by blocking the receptor of CGRP instead of binding to proteins
.
In a multi-site, randomized Phase IV study, researchers will recruit patients with paroxysmal migraine with or without aura
.
Divided into two groups, one group received monthly Emgality injections, starting at 240 mg, followed by 120 mg injections; the other group took Nurtec Disintegrating Tablets 75 mg every other day
.
The main clinical endpoint-a 50% decrease in the number of migraine days per month
.
The announcement of this news triggered a legal dispute between Teva Pharmaceuticals and Eli Lilly
.
On the same day, Teva filed a lawsuit against Eli Lilly, claiming that Emgality infringed two of its patents and demanded Eli Lilly stop manufacturing and selling CGRP inhibitors in the United States
.
In addition, Teva will be given corresponding financial compensation
.
Prior to this, Teva had accused Eli Lilly's Emgality of infringing as many as nine patents
.
The financial report for the first quarter of 2021 revealed that Teva’s Ajovy revenue was US$47 million, while Eli Lilly’s Emgality revenue was as high as US$120 million
.
News source: https://
.
Emgality is a monoclonal antibody that can selectively bind to calcitonin gene-related peptide (CGRP).
The FDA approved the preventive treatment of migraine in 2018
.
At a virtual meeting organized by the American Headache Society (AHS) in 2021, according to real data in reality, the compliance and durability of migraine patients using the drug is higher than that of oral standard treatment
.
Nurtec is an orally disintegrating tablet that patients take every other day
.
Unlike Emgality, Nurtec works by blocking the receptor of CGRP instead of binding to proteins
.
In a multi-site, randomized Phase IV study, researchers will recruit patients with paroxysmal migraine with or without aura
.
Divided into two groups, one group received monthly Emgality injections, starting at 240 mg, followed by 120 mg injections; the other group took Nurtec Disintegrating Tablets 75 mg every other day
.
The main clinical endpoint-a 50% decrease in the number of migraine days per month
.
The announcement of this news triggered a legal dispute between Teva Pharmaceuticals and Eli Lilly
.
On the same day, Teva filed a lawsuit against Eli Lilly, claiming that Emgality infringed two of its patents and demanded Eli Lilly stop manufacturing and selling CGRP inhibitors in the United States
.
In addition, Teva will be given corresponding financial compensation
.
Prior to this, Teva had accused Eli Lilly's Emgality of infringing as many as nine patents
.
The financial report for the first quarter of 2021 revealed that Teva’s Ajovy revenue was US$47 million, while Eli Lilly’s Emgality revenue was as high as US$120 million
.
News source: https://
